This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fitzpatrick, D. Articles by Espiner, E. A. Search for Related Content PubMed PubMed Citation Articles by Fitzpatrick, D. Articles by Espiner, E. A.

Circulation, Vol 67, 613-619, Copyright © 1983 by American Heart Association

ARTICLES

Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure

D Fitzpatrick, H Ikram, MG Nicholls and EA Espiner

The hemodynamic, hormonal and electrolyte effects of prenalterol, a synthetic selective beta 1 agonist, were studied in six patients with New York Heart Association functional class II and III heart failure. Prenalterol was infused incrementally at 60, 120 and 240 nmol/min, each rate for 24 hours, producing steady-state plasma prenalterol levels of 52 +/- 3, 121 +/- 6 and 194 +/- 9 nmol/1, respectively (mean +/- SEM). Hemodynamic and hormonal measurements were performed before, during and after prenalterol administration under conditions of constant body posture and a regulated intake of dietary sodium and potassium. Prenalterol induced a statistically significant increase in cardiac index (from 2.6 +/- 0.2 to 3.1 +/- 0.3 1/min/m2), with parallel increases in stroke index (from 28 +/- 2 to 34 +/- 2 ml/beat/m2). Forearm blood flow measurements increased (from 2.9 +/- 0.5 to 4.1 +/- 0.6 ml/min/100 g), while calculated systemic vascular resistance fell, as did pulmonary capillary wedge pressure (from 13.7 +/- 1.6 to 10.5 +/- 1.7 mm Hg). The drug did not alter heart rate, arterial pressure, right heart pressures or the frequency of ventricular premature beats. Prenalterol increased plasma renin activity (from 2.9 +/- 0.8 to 6.6 +/- 1.8 nmol/1/hour), angiotensin II (from 59 +/- 12 to 89 +/- 22 pmol/1), urinary aldosterone excretion (from 41 +/- 10 to 78 +/- 34 nmol/day) and plasma insulin (from 10.6 +/- 2.2 to 19.8 +/- 3.9 mU/1). Circulating catecholamines, cortisol, glucose, glucagon or pancreatic polypeptide did not change. Dose-response studies in five patients showed dose-dependent increments in hemodynamic variables, while hormonal changes plateaued at the second dose level. We conclude that prenalterol infusion augments myocardial contractility, reduces systemic vascular resistance, and stimulates insulin release and the renin-angiotensin-aldosterone system.

This article has been cited by other articles:

				H. Persson, K. Andreasson, T. Kahan, S. V. Eriksson, B. Tidgren, P. Hjemdahl, C. Hall, and L. Erhardt Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists Eur J Heart Fail, January 1, 2002; 4(1): 73 - 82. [Abstract] [Full Text] [PDF]

				M. D. Guazzi, P. G. Agostoni, E. Doria, A. Loaldi, M. Pepi, and A. Polese Hemodynamic Response to Oral Prenalterol in Dilated Decompensated Cardiomyopathy as a Result of Cardiac and Vascular Effects Angiology, December 1, 1985; 36(12): 857 - 866. [Abstract] [PDF]